Wealthspire Advisors LLC Has $1.21 Million Position in Danaher Co. (NYSE:DHR)

Wealthspire Advisors LLC boosted its holdings in Danaher Co. (NYSE:DHR) by 3.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,823 shares of the conglomerate’s stock after buying an additional 165 shares during the quarter. Wealthspire Advisors LLC’s holdings in Danaher were worth $1,205,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Oak Thistle LLC acquired a new position in shares of Danaher during the second quarter worth $363,000. Caden Capital Partners LP lifted its holdings in Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after buying an additional 15,313 shares during the period. JARISLOWSKY FRASER Ltd grew its position in shares of Danaher by 10.8% in the 4th quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after buying an additional 55,908 shares during the last quarter. HighPoint Advisor Group LLC acquired a new stake in shares of Danaher in the fourth quarter valued at about $2,614,000. Finally, Norden Group LLC acquired a new stake in shares of Danaher in the first quarter valued at about $4,151,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 over the last ninety days. 11.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

DHR has been the topic of several analyst reports. Robert W. Baird upped their target price on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Leerink Partners upped their price objective on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 target price on shares of Danaher in a research note on Friday, September 6th. Barclays boosted their target price on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Finally, TD Cowen increased their price target on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $278.94.

Danaher Trading Up 0.6 %

NYSE DHR opened at $274.25 on Monday. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The business has a 50 day moving average price of $264.55 and a 200-day moving average price of $256.51. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a market cap of $198.07 billion, a price-to-earnings ratio of 46.48, a P/E/G ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.05 earnings per share. As a group, equities analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.